Thorsten Müller

Dr. Thorsten Müller


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
TMThorsten Müller
Thorsten Müller
CCCaoimhin G. Concannon
Caoimhin G. Concannon
MWManus W. Ward
Manus W. Ward
CWCiara M. Walsh
Ciara M. Walsh
ATAnca L. Tirniceriu
Anca L. Tirniceriu
RERupert Egensperger
Rupert Egensperger
Amyloidogenic processing of the amyloid precursor protein (APP) results in the generation of β-amyloid, the main constituent of Alzheimer plaques, and the APP intracellular domain (AICD). Recently, it has been demonstrated that AICD has transactivation potential; however, the targets of AICD-dependent gene regulation and hence the physiological role of AICD remain largely unknown. We analyzed transcriptome changes during AICD-dependent gene regulation by using a human neural cell culture system inducible for expression of AICD, its coactivator FE65, or the combination of both. Induction of AICD was associated with increased expression of genes with known function in the organization and dynamics of the actin cytoskeleton, including α2-Actin and Transgelin (SM22). AICD target genes were also found to be differentially regulated in the frontal cortex of Alzheimer's disease patients compared with controls as well as in AICD/FE65 transiently transfected murine cortical neurons. Confocal image analysis of neural cells and cortical neurons expressing both AICD and FE65 confirmed pronounced changes in the organization of the actin cytoskeleton, including the destabilization of actin fibers and clumping of actin at the sites of cellular outgrowth. Our data point to a role of AICD in developmental and injury-related cytoskeletal dynamics in the nervous system.

1 November 2019 in Trends in Cell Biology
Verified
Journal Article
Closed access
HBHassan Bukhari
Hassan Bukhari
TMThorsten Müller
Thorsten Müller

1 September 2017 in Progress in Neurobiology
Verified
Journal Article
Closed access
HBHassan Bukhari
Hassan Bukhari
AGAnnika Glotzbach
Annika Glotzbach
KKKatharina Kolbe
Katharina Kolbe
GLGregor Leonhardt
Gregor Leonhardt
CLChristina Loosse
Christina Loosse
TMThorsten Müller
Thorsten Müller

23 September 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MBMaren Bormann
Maren Bormann
MAMira Alt
Mira Alt
LSLeonie Schipper
Leonie Schipper
LSLukas van de Sand
Lukas van de Sand
VLVu Thuy Khanh Le-Trilling
Vu Thuy Khanh Le-Trilling
Adalbert KrawczykAdalbert Krawczyk
Adalbert Krawczyk
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19). The availability of effective and well-tolerated antiviral drugs for the treatment of COVID-19 patients is still very limited. Traditional herbal medicines elicit antiviral activity against various viruses and might therefore represent a promising option for the complementary treatment of COVID-19 patients. The application of turmeric root in herbal medicine has a very long history. Its bioactive ingredient curcumin shows a broad-spectrum antimicrobial activity. In the present study, we investigated the antiviral activity of aqueous turmeric root extract, the dissolved content of a curcumin-containing nutritional supplement capsule, and pure curcumin against SARS-CoV-2. Turmeric root extract, dissolved turmeric capsule content, and pure curcumin effectively neutralized SARS-CoV-2 at subtoxic concentrations in Vero E6 and human Calu-3 cells. Furthermore, curcumin treatment significantly reduced SARS-CoV-2 RNA levels in cell culture supernatants. Our data uncover curcumin as a promising compound for complementary COVID-19 treatment. Curcumin concentrations contained in turmeric root or capsules used as nutritional supplements completely neutralized SARS-CoV-2 in vitro. Our data argue in favor of appropriate and carefully monitored clinical studies that vigorously test the effectiveness of complementary treatment of COVID-19 patients with curcumin-containing products.

1 January 2013 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
TMThorsten Müller
Thorsten Müller
ASAndreas Schrötter
Andreas Schrötter
CLChristina Loosse
Christina Loosse
KPKathy Pfeiffer
Kathy Pfeiffer
CTCarsten Theiss
Carsten Theiss
KMKatrin Marcus
Katrin Marcus

14 November 2011 in Journal of Proteome Research
Verified
Journal Article
Closed access
TMThorsten Müller
Thorsten Müller
ASAndreas Schrötter
Andreas Schrötter
CLChristina Loosse
Christina Loosse
SHStefan Helling
Stefan Helling
CSChristian Stephan
Christian Stephan
KMKatrin Marcus
Katrin Marcus